A Double-Blind, Placebo Controlled, Randomized, Adaptive, First-in-Human Study to Assess, Safety, Tolerability, Pharmacokinetics and Food Effect of Single and Multiple Doses of BLU-5937 Administered Orally in Healthy Male and Female
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2018
At a glance
- Drugs BLU-5937 (Primary)
- Indications Cough
- Focus Adverse reactions; First in man
- Sponsors BELLUS Health
- 19 Nov 2018 Results presented in a BELLUS Health media release.
- 08 Nov 2018 Status changed from recruiting to completed.
- 27 Jun 2018 According to a BELLUS Health media release, the study is expected to initiate in July 2018, with results expected in the fourth quarter of 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History